Page last updated: 2024-11-06

xyloidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72734
CHEMBL ID272253
SCHEMBL ID3617968
MeSH IDM0093386

Synonyms (47)

Synonym
nsc-629748
dehydro-alpha-lapachone
2,2-dimethylbenzo[g]chromene-5,10-dione
NSC629748 ,
2,2-dimethyl-2h-benzo[g]chromene-5,10-dione
xyloidone
nsc-106453
dehydro-.alpha.-lapachone
15297-92-4
.alpha.-lapachone, dehydro-
dehydro-.alpha.-lapachol
dehydro-.alpha.-lapacone
dehydrolapachone
nsc106453 ,
dehydroplapachone
2h-naphtho[2,10-dione, 2,2-dimethyl-
pyranonaphthoquinone derivative, 23
2,2-dimethyl-2h,5h,10h-benzo[g]chromene-5,10-dione
bdbm24786
CHEMBL272253
SCHEMBL3617968
AKOS024341158
2h-naphtho(2,3-b)pyran-5,10-dione, 2,2-dimethyl-
nsc 629748
dehydro-alpha-lapachol
305wy61cuf ,
nsc 106453
alpha-lapachone, dehydro-
xyloidone (van)
dehydro-alpha-lapacone
unii-305wy61cuf
2h-naphtho[2,3-b]pyran-5,10-dione, 2,2-dimethyl-
OWFHAMHRUCUSRM-UHFFFAOYSA-N
2,2-dimethyl-2h-benzo[g]chromene-5,10-dione #
DTXSID30165176
q 99 2,2-dimethyl-2h-naphtho(2,3-b)pyran-5,10-dione
2,2-dimethyl-2h-benzo [g]chromene-5,10-dione
FT-0702603
2h-naphtho(2,3-b)pyran-5,10-dione, 2,2-dimethyl- (8ci)(9ci)
ldn 22684; nsc 106453; nsc 629748; xiloidone; xyloidone; alpha-lapachone, dehydro-
ldn-22684
xiloidone
2,2-dimethyl-2h-naphtho(2,3-b)pyran-5,10-dione
allyl 3-aminopropylcarbamate
ldn 22684; nsc 106453; nsc 629748; xiloidone; xyloidone; -lapachone, dehydro-
mfcd00022286
FS-10412
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)0.21400.05373.075710.0000AID1798473; AID326467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1441542Electrochemical behavior of the compound assessed as electrochemical redox potential with reference to ferrocene at 1 mM using Ag/AgCl reference electrode measured up to -2 V at potential sweep rates of 50 mV/s by cyclic voltammetry2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID326467Inhibition of purified human recombinant IDO2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
AID380857Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID380856Antiproliferative activity against human HaCaT cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID1441541Selectivity ratio of compound reduction rate catalyzed by recombinant human NQO1 expressed in Escherichia coli to compound reduction rate catalyzed by recombinant human CPR expressed in baculovirus infected insect cells2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1441539Substrate activity at recombinant human NQO1 expressed in Escherichia coli assessed as compound reduction rate by measuring NADPH consumption per umol of enzyme preincubated for 3 mins followed by NADPH addition measured for 5 mins at 2 sec time interval 2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1441540Substrate activity at recombinant human CPR expressed in baculovirus infected insect cells assessed as compound reduction rate by measuring NADPH consumption per umol of enzyme preincubated for 3 mins followed by NADPH addition measured for 5 mins at 2 se2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1798473Enzyme Inhibition Assay from Article 10.1021/jm7014155: \\Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's1 (12.50)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]